BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 15, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ENMD-2076: Additional Phase I data

Additional data from an ongoing, open-label, dose-escalation, U.S. Phase I trial in 20 evaluable patients showed that once-daily oral ENMD-2076 produced 1 case of complete remission with incomplete hematological recovery, while 3 patients achieved a morphologic leukemia-free state. Additionally, ENMD-2076 led to reductions in marrow...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >